Last reviewed · How we verify

Nycomed — Portfolio Competitive Intelligence Brief

Nycomed pipeline: 0 marketed, 0 filed, 3 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 1 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Fentanyl (Matrifen) Fentanyl (Matrifen) phase 3 Opioid agonist Mu-opioid receptor (μ-OR) Pain Management
Fibrinogen human (TachoSil) Fibrinogen human (TachoSil) phase 3 Fibrin sealant Fibrinogen and thrombin (coagulation cascade) Surgery/Hemostasis
Nasal fentanyl Nasal fentanyl phase 3 Opioid agonist Mu-opioid receptor (OPRM1) Pain Management

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ain Shams University · 1 shared drug class
  2. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  3. Baxter Healthcare Corporation · 1 shared drug class
  4. Beijing Friendship Hospital · 1 shared drug class
  5. Cephalon · 1 shared drug class
  6. Ciusss de L'Est de l'Île de Montréal · 1 shared drug class
  7. Corporacion Parc Tauli · 1 shared drug class
  8. Aarhus University Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Nycomed:

Cite this brief

Drug Landscape (2026). Nycomed — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/nycomed. Accessed 2026-05-13.

Related